<DOC>
	<DOCNO>NCT03082235</DOCNO>
	<brief_summary>Study E6742-A001-001 randomize , double-blind , placebo-controlled , single ascend dose study conduct evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) single ascend oral dos E6742 healthy adult participant .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetics , Pharmacodynamics E6742 Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Nonsmoking , male female , age ≥18 year ≤45 year old time inform consent Body mass index ( BMI ) ≥18 &lt; 32 kilogram per meter square ( kg/m2 ) Screening Females breastfeed pregnant Screening Baseline ( document positive betahuman chorionic gonadotropin [ βhCG ] human chorionic gonadotropin [ hCG ] test minimum sensitivity 25 International Units per Liter [ IU/L ] equivalent unit βhCG [ hCG ] ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . Males successful vasectomy ( confirm azoospermia ) female partner meet criterion ( ie , childbearing potential practicing highly effective contraception throughout study period 5 time halflife study drug plus 90 day study drug discontinuation ) . No sperm donation allow study period 5 time halflife study drug plus 90 day study drug discontinuation . Any history gastrointestinal surgery may affect pharmacokinetic ( PK ) profile E6742 ( eg , hepatectomy , nephrectomy , digestive organ resection ) Screening Known history clinically significant drug allergy Screening Known history food allergy presently experience significant seasonal perennial allergy Screening Known human immunodeficiency virus ( HIV ) positive Screening Active viral hepatitis ( A , B , C ) demonstrate positive serology Screening History drug alcohol dependency abuse within 2 year prior Screening , positive urine drug alcohol test Screening Baseline Currently enrol another clinical study use investigational drug device within 30 day ( 5 halflives , whichever long ) inform consent Receipt blood product within 4 week , donation blood within 8 week , donation plasma within 1 week dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>E6742</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>